Alpha-lipoic acid induces sodium iodide symporter expression in TPC-1 thyroid cancer cell line

Nuclear Medicine and Biology

Volumn 39, Issue 8, 2012, Pages 1275-1280

  Choi, Hyun Jeung ^a   Kim, Tae Yong ^a   Ruiz Llorente, Sergio ^b   Jeon, Min Ji ^a   Han, Ji Min ^a   Kim, Won Gu ^a   Shong, Young Kee ^a   Kim, Won Bae ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Alpha lipoic acid; Antioxidant; Differentiation; Iodide; Sodium iodide symporter; Thyroid neoplasm

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; IODINE; MESSENGER RNA; SODIUM IODIDE SYMPORTER; THIOCTIC ACID; TRICHOSTATIN A;

ARTICLE; ASSAY; CANCER CELL; CELL MEMBRANE TRANSPORT; CELL NUCLEUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; GENE; GENE ACTIVITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; IODINE UPTAKE ASSAY; NIS GENE; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; THYROID CANCER;

ANTIOXIDANTS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SPACE; IODIDES; PROMOTER REGIONS, GENETIC; PROTEIN TRANSPORT; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; SIGNAL TRANSDUCTION; SYMPORTERS; THIOCTIC ACID; THYROID NEOPLASMS;

EID: 84867847230     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.08.007     Document Type: Article

References (38)

1. Mazzaferri E.L., Jhiang S.M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994, 97:418-428.
2. Grebe S.K., Hay I.D. Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am 1996, 5:43-63.
3. Goretzki P.E., Simon D., Frilling A., Witte J., Reiners C., Grussendorf M., et al. Surgical reintervention for differentiated thyroid cancer. Br J Surg 1993, 80:1009-1012.
4. Filetti S., Bidart J.M., Arturi F., Caillou B., Russo D., Schlumberger M. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol 1999, 141:443-457.
5. Durante C., Haddy N., Baudin E., Leboulleux S., Hartl D., Travagli J.P., et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006, 91:2892-2899.
6. Kogai T., Taki K., Brent G.A. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr Relat Cancer 2006, 13:797-826.
7. Grüning T., Tiepolt C., Zöphel K., Bredow J., Kropp J., Franke W.-G. Retinoic acid for redifferentiation of thyroid cancer-does it hold its promise?. Eur J Endocrinol 2003, 148:395-402.
8. Courbon F., Zerdoud S., Bastie D., Archambaud F., Hoff M., Eche N., et al. Defective efficacy of retinoic acid treatment in patients with metastatic thyroid carcinoma. Thyroid 2006, 16:1025-1031.
9. Kim W.G., Kim E.Y., Kim T.Y., Ryu J.-S., Hong S.J., Kim W.B., et al. Redifferentiation therapy with 13-cis retinoic acids in radioiodine-resistant thyroid cancer. Endocr J 2009, 56:105-112.
10. Tepmongkol S., Keelawat S., Honsawek S., Ruangvejvorachai P. Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-gamma. Thyroid 2008, 18:697-704.
11. Kebebew E., Lindsay S., Clark O.H., Woeber K.A., Hawkins R., Greenspan F.S. Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer. Thyroid 2009, 19:953-956.
12. Perham R.N. Swinging arms and swinging domains in multifunctional enzymes: catalytic machines for multistep reactions. Annu Rev Biochem 2000, 69:961-1004.
13. Simbula G., Columbano A., Ledda-Columbano G.M., Sanna L., Deidda M., Diana A., et al. Increased ROS generation and p53 activation in alpha-lipoic acid-induced apoptosis of hepatoma cells. Apoptosis 2007, 12:113-123.
14. Wenzel U., Nickel A., Daniel H. alpha-Lipoic acid induces apoptosis in human colon cancer cells by increasing mitochondrial respiration with a concomitant O2-*-generation. Apoptosis 2005, 10:359-368.
15. van de Mark K., Chen J.S., Steliou K., Perrine S.P., Faller D.V. Alpha-lipoic acid induces p27Kip-dependent cell cycle arrest in non-transformed cell lines and apoptosis in tumor cell lines. J Cell Physiol 2003, 194:325-340.
16. Dozio E., Ruscica M., Passafaro L., Dogliotti G., Steffani L., Marthyn P., et al. The natural antioxidant alpha-lipoic acid induces p27(Kip1)-dependent cell cycle arrest and apoptosis in MCF-7 human breast cancer cells. Eur J Pharmacol 2010, 641:29-34.
17. Sokoloski J.A., Hodnick W.F., Mayne S.T., Cinquina C., Kim C.S., Sartorelli A.C. Induction of the differentiation of HL-60 promyelocytic leukemia cells by vitamin E and other antioxidants in combination with low levels of vitamin D3: possible relationship to NF-kappaB. Leukemia 1997, 11:1546-1553.
18. Kim D.W., Jo Y.S., Jung H.S., Chung H.K., Song J.H., Park K.C., et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006, 91:4070-4076.
19. Meireles A.M., Preto A., Rocha A.S., Rebocho A.P., Máximo V., Pereira-Castro I., et al. Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines. Thyroid 2007, 17:707-715.
20. Kim W.B., Lewis C.J., McCall K.D., Malgor R., Kohn A.D., Moon R.T., et al. Overexpression of Wnt-1 in thyrocytes enhances cellular growth but suppresses transcription of the thyroperoxidase gene via different signaling mechanisms. J Endocrinol 2007, 193:93-106.
21. Suzuki K., Mori A., Ishii K.J., Saito J., Singer D.S., Klinman D.M., et al. Activation of target-tissue immune-recognition molecules by double-stranded polynucleotides. Proc Natl Acad Sci U S A 1999, 96:2285-2290.
22. Taki K., Kogai T., Kanamoto Y., Hershman J.M., Brent G.A. A thyroid-specific far-upstream enhancer in the human sodium/iodide symporter gene requires Pax-8 binding and cyclic adenosine 3',5'-monophosphate response element-like sequence binding proteins for full activity and is differentially regulated in normal and thyroid cancer cells. Mol Endocrinol 2002, 16:2266-2282.
23. Luciani P., Buci L., Conforti B., Tonacchera M., Agretti P., Elisei R., et al. Expression of cAMP response element-binding protein and sodium iodide symporter in benign non-functioning and malignant thyroid tumours. Eur J Endocrinol 2003, 148:579-586.
24. García B., Santisteban P. PI3K is involved in the IGF-I inhibition of TSH-induced sodium/iodide symporter gene expression. Mol Endocrinol 2002, 16:342-352.
25. Ziegler D., Hanefeld M., Ruhnau K.J., Meissner H.P., Lobisch M., Schütte K., et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 1995, 38:1425-1433.
26. Novotny L., Rauko P., Cojocel C. alpha-Lipoic acid: the potential for use in cancer therapy. Neoplasma 2008, 55:81-86.
27. Teichert J., Hermann R., Ruus P., Preiss R. Plasma kinetics, metabolism, and urinary excretion of alpha-lipoic acid following oral administration in healthy volunteers. J Clin Pharmacol 2003, 43:1257-1267.
28. Cremer D.R., Rabeler R., Roberts A., Lynch B. Safety evaluation of alpha-lipoic acid (ALA). Regul Toxicol Pharmacol 2006, 46:29-41.
29. Puppin C., Arturi F., Ferretti E., Russo D., Sacco R., Tell G., et al. Transcriptional regulation of human sodium/iodide symporter gene: a role for redox factor-1. Endocrinology 2004, 145:1290-1293.
30. Ringel M.D., Anderson J., Souza S.L., Burch H.B., Tambascia M., Shriver C.D., et al. Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer. Mod Pathol 2001, 14:289-296.
31. Ward L.S., Santarosa P.L., Granja F., da Assumpção L.V.M., Savoldi M., Goldman G.H. Low expression of sodium iodide symporter identifies aggressive thyroid tumors. Cancer Lett 2003, 200:85-91.
32. Ohno M., Zannini M., Levy O., Carrasco N., di Lauro R. The paired-domain transcription factor Pax8 binds to the upstream enhancer of the rat sodium/iodide symporter gene and participates in both thyroid-specific and cyclic-AMP-dependent transcription. Mol Cell Biol 1999, 19:2051-2060.
33. Dohán O., Carrasco N. Advances in Na(+)/I(-) symporter (NIS) research in the thyroid and beyond. Mol Cell Endocrinol 2003, 213:59-70.
34. Trapasso F., Iuliano R., Chiefari E., Arturi F., Stella A., Filetti S., et al. Iodide symporter gene expression in normal and transformed rat thyroid cells. Eur J Endocrinol 1999, 140:447-451.
35. Wang J., Knauf J.A., Basu S., Puxeddu E., Kuroda H., Santoro M., et al. Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels. Mol Endocrinol 2003, 17:1425-1436.
36. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001, 1:194-202.
37. Brabant G., Maenhaut C., Köhrle J., Scheumann G., Dralle H., Hoang-Vu C., et al. Human thyrotropin receptor gene: expression in thyroid tumors and correlation to markers of thyroid differentiation and dedifferentiation. Mol Cell Endocrinol 1991, 82:R7-R12.
38. Spitzweg C., Harrington K.J., Pinke L.A., Vile R.G., Morris J.C. Clinical review 132: the sodium iodide symporter and its potential role in cancer therapy. J Clin Endocrinol Metab 2001, 86:3327-3335.